Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of teriparatide peptide in China. Welcome to wholesale bulk high quality teriparatide peptide for sale here from our factory. Good service and reasonable price are available.
Teriparatide peptide is a 34-amino-acid polypeptide drug. Its essence is the active N-terminal fragment of recombinant human parathyroid hormone (PTH). As a bone anabolic regulator, it can uniquely regulate bone metabolism in both directions: through intermittent subcutaneous administration, it can preferentially activate osteoblast activity and significantly stimulate new bone formation, unlike traditional anti-absorption drugs that only inhibit osteoclast activity. This mechanism enables it to effectively increase the number of bone trabeculae, improve bone microstructure, and enhance bone density and bone strength. Clinically, it is mainly used to treat severe osteoporosis with a high risk of fractures, especially in postmenopausal women and male patients, where it can significantly reduce the incidence of vertebral and non-vertebral fractures. Due to its potential risk of osteosarcoma, the treatment course is usually limited to within two years and is strictly supervised by specialist doctors, representing an important milestone in targeted treatment for osteoporosis.
|
|
|
Teriparatide Powder COA
Comparison of the molecular mechanisms of drugs promoting bone formation and anti-bone resorption
The bone-promoting mechanism of teriparatide
Teriparatide is the amino-terminal 1-34 fragment (rhPTH1-34) of recombinant human parathyroid hormone (PTH), with a molecular weight of 4117.8 Da. Natural PTH is composed of 84 amino acids, while teriparatide retains the core region of its biological activity and can specifically bind to the PTH1 receptor (PTH1R) on the surface of bone cells.
Signal transduction Pathway
After teriparatide binds to PTH1R, it activates the Gs protein-mediated cAMP/PKA classical signaling pathway and simultaneously activates the β -arrestin-dependent non-classical signaling pathway. This dual-pathway regulatory mechanism enables it to:
Directly stimulate osteoblast differentiation: Up-regulate the expressions of alkaline phosphatase (ALP), osteocalcin (OCN), and type I collagen (COL1A1), and promote matrix mineralization;
Regulate bone resorption balance: Inhibit osteoclast activity through the IGF-1 autocrine circuit to avoid excessive bone resorption;
Improving bone microstructure: Increasing the thickness and connectivity of trabeculae, significantly enhancing bone quality.
Dynamic Regulation of Bone Reconstruction
The effect of teriparatide is time-dependent:
Early stage (1-3 months) : Mainly promotes the proliferation and differentiation of osteoblasts, and bone formation markers (such as PINP) significantly increase;
Mid-term (3-6 months) : Bone formation and bone resorption reach a dynamic balance, and bone mineral density (BMD) begins to increase steadily;
Long-term (>12 months) : Continuously improve bone microstructure and reduce the risk of fractures.
Molecular Mechanisms of Anti-bone resorption Drugs
Anti-bone resorption drugs reduce bone loss by inhibiting osteoclast activity and mainly include the following categories:
Bisphosphonates
Bisphosphonates inhibit osteoclast-mediated bone resorption by binding to bone hydroxyapatite. Its mechanism of action includes:
Inhibition of Farnesic pyrophosphate synthase (FPPS) : Blocking the isoprene of small G protein in osteoclasts, leading to osteoclast apoptosis;
Inducing osteoclast apoptosis: by activating the mitochondrial pathway or the death receptor pathway;
Inhibit osteoclast recruitment: Reduce the expression of RANKL and inhibit the differentiation of osteoclast precursors.
Denosumab
Disumab is a fully humanized RANKL monoclonal antibody that inhibits osteoclast differentiation and activation by blocking the RANkL-RANK signaling pathway. Its characteristics include:
High-affinity bound RANKL: The dissociation constant (Kd) is 10^-12 M, which is much higher than that of natural OPG;
Rapidly reduce bone turnover markers: CTX levels can be significantly reduced within 3 days after administration;
Reversible effect: Bone turnover markers can return to baseline levels within 6 to 12 months after drug withdrawal.
Calcitonins
Calcitonin inhibits osteoclast activity by binding to the calcitonin receptor (CTR) on the surface of osteoclasts. Its mechanism of action includes:
Activate the cAMP/PKA pathway: Reduce the intracellular calcium ion concentration in osteoclasts and inhibit cytoskeletal rearrangement;
Reduce the number of osteoclasts: Inhibit the proliferation and differentiation of osteoclast precursors;
Central analgesic effect: Relieves bone pain by activating opioid receptors in the hypothalamus.
Mechanism comparison and summary
Comparison of clinical efficacy
Changes in bone mineral density (BMD)
The BMD enhancement effect of teriparatide
Clinical studies have shown that teriparatide treatment can significantly increase BMD in the lumbar spine and hip.
Lumbar BMD
On average, it increased by 9.7%-13.5% after 18 months of treatment;
Total hip BMD
It increased by an average of 2.6%-6.2% after 18 months of treatment;
Femoral neck BMD
The average increase was 2.8%-5.5% after 18 months of treatment.
The BMD maintenance effect of anti-bone resorption drugs
Bisphosphonates
After 3 years of treatment, the lumbar BMD increased by 5.3%-8.8%, and the hip BMD increased by 2.2%-6.2%.
Desumab
After 3 years of treatment, lumbar BMD increased by 9.2%, and total hip BMD increased by 6.0%.
Calcitonin
After one year of treatment, the lumbar BMD increased by approximately 1% to 2%, and the effect was significantly weaker than that of other drugs.
Reduced risk of fractures
The fracture prevention effect of teriparatide
Vertebral fractures: Reduced risk by 65% (vs. placebo);
Non-vertebral fractures: Reduced risk by 53% (vs. placebo);
Clinical fractures: Reduced risk by 55% (vs. placebo).
The fracture prevention effect of anti-bone resorption drugs
Bisphosphonates:
Vertebral fractures: Reduce risk by 40%-70%;
Non-vertebral fractures: Reduce risk by 20%-50%;
Desumab
Vertebral fractures: Reduce risk by 68%;
Non-vertebral fractures: Reduce risk by 20%;
Calcitonins
Vertebral fractures: Reduce the risk by approximately 36% only in postmenopausal women;
Non-vertebral fractures: No significant reduction effect.
Comparison and summary of therapeutic Effects
Safety and adverse reactions
Safety Considerations of Teriparatide peptide
Risk of osteosarcoma
Animal experiments have shown that long-term high-dose use of teriparatide may increase the risk of osteosarcoma, but human clinical trials have not confirmed the correlation. The FDA has lifted the lifetime cumulative treatment limit of no more than 24 months, but the domestic instructions still retain this limit.
Hypercalcemia
The incidence of hypercalcemia during teriparatide treatment was approximately 11%, and it was more common in patients with renal insufficiency. Blood calcium levels need to be monitored. Medication should be suspended if necessary.
Other Adverse reactions
Nausea (about 11%), limb pain (about 7%), headache (about 6%);
Injection site reactions (about 3%), mostly mild to moderate;
Orthostatic hypotension (rare, incidence <1%).
Safety Considerations of Anti-Bone resorption Drugs
Bisphosphonates
Acute phase reactions: Fever, myalgia, arthralgia (incidence rate approximately 10%-30%);
Mandibular osteonecrosis (ONJ) : The incidence rate is approximately 0.1%-1%, and it is positively correlated with the duration of medication.
Atypical femoral fractures (AFF) : The risk increases with long-term use (>3 years), with an incidence rate of approximately 0.03%-0.1%.
Desumab
Hypocalcemia: The incidence rate is approximately 1.7%, and calcium supplements and vitamin D are required.
ONJ: The incidence rate is approximately 1%-2%, which is higher than that of bisphosphonates.
Bone loss rebound after drug withdrawal: The risk of vertebral fractures increases within one year after drug withdrawal.
Calcitonins
Risk of malignant tumors: Long-term use (>6 months) may increase the risk of malignant tumors (OR=1.43);
Allergic reaction: The incidence rate is approximately 0.1% to 1%. In severe cases, drug withdrawal is required.
Summary of Safety Comparison
Clinical application guidelines and recommendations
Applicable Population
According to the "Chinese Expert Consensus on the Treatment of Osteoporotic Fractures with teriparatide (2024 Edition)", the following patients are recommended to use teriparatide peptide first:
Patients with extremely high risk of fractures
Recently, brittle fractures (such as fractures of the hip, vertebral body, and distal radius) occurred;
Multiple osteoporotic fractures
Fractures still occurred during the anti-osteoporosis treatment.
Patients with osteoporotic fractures during the perioperative period
Early use can promote fracture healing and reduce the risk of internal fixation failure.
Patients with low bone turnover osteoporosis
When the efficacy of traditional anti-bone resorption drugs is unsatisfactory, switching treatment can be considered.
Treatment Plan
Recommended dosage: 20μg/ day, subcutaneous injection, with a treatment course not exceeding 24 months;
Elderly patients: No need to adjust the dosage according to age;
Patients with renal insufficiency: Use with caution if eGFR<30ml/min, and closely monitor the blood calcium level.
Sequential treatment: After discontinuation of teriparatide, anti-bone resorption drugs should be used sequentially to maintain or further increase BMD.
Contraindications
Absolute contraindications:
Osteitis deformis
History of radiotherapy for bone diseases
Bone metastasis of tumor
Hypercalcemia
Severe renal insufficiency (eGFR<15ml/min)
Adolescents under the age of 18 and those with unclosed epiphyses.
Relative contraindications:
Pregnant and lactating women
Primary hyperparathyroidism.
Future Research directions
Long-acting preparations and New Administration methods
Sustained-release microsphere preparations: By encapsulating drugs with high-molecular materials such as PLGA, they can be administered once a week or once a month, thereby enhancing patient compliance.
Transdermal patches: In the Phase II clinical research stage, they are expected to improve the convenience of medication for elderly patients.
Local sustained-release systems: such as PTH-collagen composite materials, used for fracture repair and promoting bone healing.
Individualized Treatment and Genotyping
PTH1R polymorphism: The variation at the rs10500783 locus can affect the therapeutic effect of teriparatide, and genotyping is helpful for screening the dominant population.
Artificial intelligence prediction model: Integrating FRAX® score, bone turnover markers and multi-gene score to achieve individualized treatment decisions.
Optimization of Combined treatment strategies
Teriparatide + bisphosphonates: Sequential treatment can significantly increase BMD in the lumbar spine and hip.
Teriparatide + desumab: The combined treatment for one year can significantly increase hip BMD, but there is no data on the reduction of fracture risk.
Short-term combined therapy: It is applicable to patients with newly diagnosed fractures or during the perioperative period, but the cost and benefits need to be weighed.
Conclusion
Teriparatide peptide, as the only approved bone-promoting drug at present, fundamentally improves bone microstructure by directly stimulating the activity of osteoblasts, providing a new treatment option for patients with extremely high fracture risk. The combined application strategy of it with anti-bone resorption drugs can achieve the dual goals of rapidly increasing BMD and maintaining therapeutic effect in the long term. In the future, with the development of long-acting preparations and the advancement of individualized treatment strategies, teriparatide is expected to play a more significant role in the treatment of osteoporosis. However, its safety monitoring still requires continuous attention, especially the long-term assessment of osteosarcoma risk. Clinicians should strictly master the indications and contraindications, and reasonably formulate treatment plans to maximize the benefits for patients.
Hot Tags: teriparatide peptide, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, CJC 1295 Peptide, Melanotan 2 Powder, Kisspeptin powder, DecaPeptide 12 CAS 137665 91 9, Epitalon Powder CAS 307297 39 8, LONG R3 IGF I CAS 143045 27 6